Cell and gene therapies depend on living cells, which makes quality testing very different from testing traditional medicines. A small change in cell composition can affect product identity, safety, or performance. Manufacturers need reliable methods to confirm that the right cells are present at the right levels throughout development and production. One of the most widely used tools for this purpose is flow cytometry immunophenotyping. It helps scientists examine cell populations in detail and verify key product attributes. As regulatory expectations continue to grow, strong characterization methods play an important role in supporting the quality and consistency of Advanced Therapy Products.

Why Cell Characterization Matters in Modern Therapy Development

Cell-based therapies contain complex and highly variable biological material. Unlike conventional drugs, they cannot be fully defined through chemical analysis alone. Manufacturers need clear evidence that the final product contains the intended cells and meets predefined specifications.

Before any product reaches a patient, several questions must be answered. The composition of the cell population must be understood and documented. Consistent characterization helps reduce uncertainty during development and manufacturing.

Here are some of the key areas that require evaluation:

• Cell identity
• Cell purity
• Cell viability
• Population distribution
• Presence of unwanted cells
• Consistency between manufacturing batches

These measurements help create a clearer understanding of the product being developed. They also provide data that can support process improvements and regulatory submissions. Without detailed characterization, it becomes difficult to demonstrate product consistency across different manufacturing runs.

The Growing Need for Strong Analytical Testing

The advanced therapy sector continues to expand, bringing greater attention to product quality and analytical control. As therapies move from research settings into commercial manufacturing, testing requirements become more rigorous.

Regulatory agencies now expect developers to provide stronger evidence linking product characteristics to manufacturing consistency. This has increased the importance of analytical methods that generate detailed and reproducible data.

Several factors are driving the demand for stronger testing programs:

• Growth in cell and gene therapy pipelines
• Increased regulatory scrutiny
• Larger commercial manufacturing operations
• More complex therapy designs
• Greater focus on product comparability

The trend is visible across the industry. According to Precedence Research, the global Advanced Therapy Medicinal Products market is projected to reach approximately USD 49.11 billion in 2026 and continue growing significantly through the next decade.

As more products enter late-stage development, testing strategies must provide deeper insight into product quality. Reliable analytical data also supports manufacturing decisions, process validation, and long-term product control.

Understanding Flow Cytometry in Therapy Manufacturing

Modern cell therapy manufacturing relies on tools that can evaluate individual cells quickly and accurately. Standard bulk testing methods often cannot provide enough detail about complex cell populations.

This is where flow cytometry becomes particularly useful. The technology examines cells one at a time and measures specific characteristics using fluorescent markers.

The technique can be used to assess:

• Cell identity
• Cell viability
• Protein expression
• Cell activation status
• Population frequency
• Manufacturing consistency

In practical terms, thousands of cells can be analyzed within seconds. This provides a detailed view of the product that would be difficult to achieve through many other analytical methods. As manufacturing processes become more sophisticated, the need for detailed cellular data continues to increase.

How Flow Cytometry Immunophenotyping Supports Product Quality

Maintaining product quality requires accurate confirmation of cellular composition. For many therapy developers, identity testing is one of the most important parts of quality control.

Flow cytometry immunophenotyping allows scientists to identify specific cell populations by measuring marker expression. This helps verify that the intended cells are present while also detecting unwanted populations that could affect product quality.

Therapy Type	Common Markers Evaluated	Purpose
CAR-T Cell Therapy	CD3, CD4, CD8, CAR markers	Verify engineered T-cell populations
Stem Cell Therapy	CD34, CD45, CD90, CD105	Confirm stem cell identity
NK Cell Therapy	CD56, CD16, CD3	Measure natural killer cell composition
Dendritic Cell Therapy	CD80, CD86, HLA-DR	Assess maturation status
Regulatory T Cell Therapy	CD4, CD25, FOXP3	Confirm target regulatory populations

The resulting data can support release testing, process monitoring, and product characterization activities. At organizations such as Xellera Therapeutics, these analytical approaches help build a stronger understanding of cell-based products throughout development.

Key Applications Across the Product Lifecycle

Analytical testing supports decision-making from the earliest development stages through commercial manufacturing. Different testing goals exist at different points in the product lifecycle.

• Raw Material Assessment

The quality of the starting material influences everything that follows. Cell composition at the collection stage can affect manufacturing efficiency, product yield, and final quality outcomes. Early characterization helps identify potential concerns before processing begins.

To understand starting material suitability, laboratories commonly assess:

• Initial cell populations
• Donor cell composition
• Cell viability levels
• Sample integrity
• Population variability

These results provide a baseline for future comparisons. They also help manufacturers establish acceptance criteria for incoming materials. Early detection of quality issues can reduce downstream manufacturing risks.

• In-Process Monitoring

Cell populations change continuously during manufacturing. Expansion, activation, and genetic modification steps can alter cell characteristics in meaningful ways. Monitoring these changes allows teams to understand how the process is performing.

The following measurements are often used during production:

• Cell expansion trends
• Population shifts
• Marker expression changes
• Transduction efficiency
• Viability monitoring

These data points help identify unexpected process changes before they affect the final product. They also support process optimization efforts and strengthen manufacturing control strategies.

• Final Product Release

Before a therapy can be released, manufacturers must confirm that predefined quality requirements have been met. Release decisions depend on objective analytical evidence rather than assumptions.

Several key attributes are commonly reviewed during release testing:

• Product identity
• Cell purity
• Viability levels
• Target cell frequency
• Residual unwanted populations

The final dataset forms part of the product release package. These results help demonstrate that manufacturing specifications have been achieved and documented appropriately.

• Stability Studies

Cell therapies can change during storage and transportation. Stability programs help determine whether important product attributes remain within acceptable limits over time. This information supports shelf-life claims and storage requirements.

Typical stability evaluations may include:

• Cell viability retention
• Marker stability
• Population consistency
• Product integrity
• Storage impact assessment

Long-term monitoring provides evidence that the product remains suitable for patient use throughout its approved storage period. It also helps manufacturers refine storage conditions and handling procedures.

Regulatory Expectations for Cell-Based Therapies

Regulators expect manufacturers to understand their products in detail. Cell characterization data helps support claims related to identity, quality, and manufacturing consistency.

Authorities also expect testing methods to be scientifically justified and properly validated. Analytical approaches should generate reproducible results that can withstand regulatory review.

Key regulatory focus areas include:

• Product identity confirmation
• Assay validation
• Defined specifications
• Process consistency
• Data integrity
• Documentation controls

Regulators continue to place greater emphasis on analytical understanding throughout product development. Strong characterization programs help manufacturers build confidence in their quality systems and support regulatory submissions more effectively.

Challenges in Cell Population Analysis

Cell characterization offers valuable insights, but it also presents technical and operational challenges. These challenges become more significant as products grow more complex.

• Complex Cellular Heterogeneity

Many therapies contain multiple cell populations with different biological properties. Small manufacturing changes can influence marker expression and population balance. This creates challenges when defining consistent product specifications.

Some common sources of variability include:

• Donor-to-donor differences
• Cell activation states
• Manufacturing conditions
• Expansion duration
• Biological variability

These factors can affect how cell populations appear during analysis. Understanding their impact helps developers build more reliable testing strategies and realistic acceptance criteria.

• Limited Sample Availability

Testing material is often limited, especially during clinical development. Every sample used for analysis reduces the amount available for manufacturing or additional studies. This places pressure on analytical teams to maximize data generation.

Laboratories often address this issue by focusing on:

• Efficient panel design
• Minimal sample consumption
• Optimized workflows
• Prioritized testing plans
• Data-rich assays

Careful planning helps balance testing needs with material availability. Efficient assay design can generate meaningful results while preserving valuable product material.

• Assay Standardization

Results must remain consistent across instruments, analysts, and manufacturing sites. Variability in procedures can create challenges when comparing data between studies or facilities.

Standardization efforts typically focus on:

• Instrument settings
• Reagent qualification
• Gating strategies
• Training programs
• Data review procedures

Well-controlled methods improve reproducibility and reduce uncertainty. They also support technology transfer activities and multi-site manufacturing operations.

Best Practices for Reliable Results

Strong analytical performance requires more than advanced instruments. Reliable data depends on well-designed procedures, trained personnel, and consistent execution.

• Use Qualified Reagents

Reagent quality directly affects analytical performance. Poor-quality antibodies can generate inconsistent or misleading results. Careful reagent selection supports data reliability.

Key considerations include:

• Supplier qualification
• Lot consistency
• Stability monitoring
• Performance verification
• Storage controls

Routine reagent evaluation helps reduce variability over time. It also strengthens confidence in analytical findings generated during product development.

• Validate Analytical Methods

Validation demonstrates that an assay performs as intended. Regulatory agencies expect manufacturers to understand assay capabilities and limitations. Validation also supports long-term method reliability.

Validation activities commonly assess:

• Accuracy
• Precision
• Specificity
• Robustness
• Reproducibility

A validated method provides stronger scientific support for decision-making. It also reduces uncertainty during regulatory review and inspection activities.

Integrate Multiple Quality Controls

No single test can fully characterize a complex therapy product. Manufacturers often combine different analytical approaches to create a broader quality assessment framework.

This may include:

• Cellular characterization
• Potency testing
• Stability evaluation
• Sterility assessment
• Compendial testing

Combining multiple data sources provides a more complete picture of product quality. It also helps ensure that different risk areas are evaluated appropriately before product release.

• Strengthen Data Governance

Data quality is as important as assay performance. Regulatory inspectors increasingly review how analytical data are collected, stored, reviewed, and approved. Strong governance supports long-term compliance.

Important controls include:

• Audit trails
• Electronic records
• Controlled procedures
• Data review workflows
• Documentation management

Reliable data systems improve traceability and reduce compliance risks. They also help organizations respond more efficiently during inspections and regulatory audits.

Conclusion

The continued growth of Advanced Therapy Products has increased the need for detailed and reliable cell characterization. Accurate analytical data helps manufacturers understand product composition, monitor manufacturing consistency, and support regulatory expectations. Methods such as flow cytometry immunophenotyping provide valuable insight into cell populations across development and production. When combined with validated assays, strong quality systems, and appropriate compendial testing, manufacturers can build a more complete understanding of product quality. As advanced therapies continue to expand, organizations such as Xellera Therapeutics will rely on scientifically sound characterization strategies to support safe, consistent, and well-controlled products.